Prestige Consumer Healthcare Inc. (PBH)

From the record

Prestige Consumer Healthcare Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Prestige Consumer Healthcare Inc.'s 10 filed years say what it did: revenue went from $882 million in fiscal 2017 to $1.1 billion in fiscal 2026, up 2.4% a year; it rose in 4 of 9 years; the deepest fall was 9% from fiscal 2018 to fiscal 2021; net income was positive in 8 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2026-03-31, Prestige Consumer Healthcare Inc.'s diluted share count shrank about 0.8% a year, and dividends and buybacks returned about 31% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 8 sales (5 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2026-03-31, Prestige Consumer Healthcare Inc. earned about 10 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 17 cents per dollar of everything the company owns. Leverage: it owed about 46 cents per dollar of assets, and net share issuance: its share count shrank 2.7% over the year (the filed statements).

From the record

Prestige Consumer Healthcare Inc.'s standing among 315 graded names in its industry family: revenue of $1.1 billion in fiscal 2026 ranks in the top 11% by size; a net margin of 17.5% ranks in the top 12%; revenue growth of -1.2% a year over the last 3 filed years ranks in the bottom 36% (its annual reports).

From the record

Prestige Consumer Healthcare Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Lombardi, Ronald M. (Chief Executive Officer, as filed), filing under that title since 2016-05-11, 10.5 years (top 16% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 7.5 years (top 23%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 26%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Prestige Consumer Healthcare Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $64 million against debt of $994 million leaves -26.6% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is 22.6% of revenue (top 10%); a gross margin of 54.7% (bottom 30%) (its annual report).

From the record

Prestige Consumer Healthcare Inc.'s growth drivers, from the filed years to fiscal 2026: revenue grew -1.2% a year over the last three filed years against 2.4% over all 10, slowing (bottom 47% of its family); the newest year grew -4.3% (bottom 33%); capital spending grew 12.8% a year (top 29%) (its annual reports). Prestige Consumer Healthcare Inc. reported 2 lines of business in fiscal 2026: North American OTC Healthcare at $914 million (84%), International OTC Healthcare at $175 million (16%); 0 of 2 grew against the year before (its annual report).

From the record

Prestige Consumer Healthcare Inc.'s newest year against its own record: revenue of $1.1 billion in fiscal 2026 came in 4.7% below the $1.1 billion its prior three years' pace pointed to (bottom 45% of its family); net income of $190 million against a prior three-year average of $114 million (top 26%); a net margin of 17.5% against 10.1% before (bottom 47%) (its annual reports).